吉非替尼二线治疗晚期肺腺癌疗效观察

目的:评价吉非替尼二线治疗晚期肺腺癌的疗效及不良反应。方法:32例晚期肺腺癌应用含铂类方案治疗失败后,口服吉非替尼250mg,1次/日,直至进展。30天后评价疗效及不良反应。结果:32例患者中,完全缓解(CR)1例,部分缓解(PR)18例,有效率(RR)为59.4%,稳定(SD)7例,疾病控制率(DCR)为81.35,进展(PD)6例。中位无疾病进展时间(PFS)7个月,1年生存率为56.3%,中位生存时间(OS)为13个月。不良反应主要为皮疹、腹泻,不影响治疗。结论:吉非替尼治疗晚期肺癌疗效好,不良反应能够耐受。

Objective：To evaluate the efficacy and toxicity of gefitinib as the second-line therapy in the patients with lung adenocarcinoma.Methods：32cases with chemo-refractory were administered gefitinib 250mg orally once a day until disease progression.Tumor response and treatment toxicities were evaluated monthly.Results：Complete regression was seen in one patient.partial response and stable disease were respectively 18and 7patients.The median PFS was 7months.One year survival rate was 56.3%.Median OS was 13 months.The most adverse reactions were mild rash and diarrhea.Conclusion：Gefitinib as the second-line therapy in advanced lung adenocarcinoma is effective.It is well tolerated with adverse reaction.